Important precautions include: GLP-1 receptor agonists should not be used in patients with type 1 diabetes or diabetic ketoacidosis Caution is advised in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 These medications are not recommended in severe gastrointestinal disease They should not be used during pregnancy or breastfeeding, and semaglutide should be discontinued at least 2 months before a planned pregnancy [1] [7] Your GP or specialist will assess your individual circumstances to determine suitability
ImproBiome provides both soluble and fermentable fibers that work together to promote comfortable, regular elimination
Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose
Research in mice suggests that coffee increases the release of GLP-1
131,132,133 MSCs have been shown to directly degrade Keap1 and activate Nrf2 activity, which increases the levels of HO-1 and NQO-1, inhibits the infiltration of colonic inflammatory cells and the expression of proinflammatory cytokines, and maintains the permeability of the mucosal barrier of colon epithelial cells
